Zevra Therapeutics, Inc. (ZVRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Zevra Therapeutics, Inc. (ZVRA) closed at USD 10.27 on 2026-10-15, a change of +1.5 % over the past year, with a market capitalization of USD 590.27M.

Zevra Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Zevra Therapeutics, Inc. key figures

Previous close

USD 10.27 (2026-10-15)

1-year change

+1.5 %

Market cap

USD 590.27M

Enterprise value

USD 370.2M

P/E ratio (trailing)

10.80

P/E ratio (forward)

9.23

EPS (trailing)

0.92

EPS (forward)

1.08

PEG ratio

10.67

Price to book

2.71

Revenue growth

53.3 %

Earnings growth

-88.4 %

Dividend per share (trailing)

0.00

Short ratio

7.45

Employees

61

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Zevra Therapeutics, Inc. and compare it with other stocks.